Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Sheldon L. Koenig, President and CEO of Esperion Therapeutics, Inc. (NASDAQ:ESPR), has sold a portion of his holdings in the company. According to a recent SEC filing, Koenig sold 13,047 shares of common stock on March 18, 2025, at a price of $1.504 per share, amounting to a total transaction value of $19,622. The transaction occurred as the stock trades near $1.67, with the company showing strong revenue growth of 186% over the last twelve months despite challenging market conditions. InvestingPro analysis indicates the company maintains a GOOD overall financial health score. This sale was conducted to satisfy tax obligations on vested shares of restricted stock units. Following the transaction, Koenig retains direct ownership of 1,571,962 shares in the company. According to InvestingPro data, Esperion operates with significant debt levels, and analysts don’t expect profitability this year. For deeper insights into ESPR’s financial health and future prospects, access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Esperion Therapeutics reported significant developments in its financial and operational performance. The company announced a 114% year-over-year increase in fourth-quarter 2024 revenue, reaching $69.1 million, surpassing the forecast of $63.45 million. This growth was driven by a 52% increase in U.S. net product revenue and a 227% surge in collaboration revenue. Earnings per share were reported at -$0.11, better than the anticipated -$0.14. Esperion ended the fiscal year with approximately $145 million in cash, positioning it well for future investments. Despite U.S. net product sales for the quarter falling short of some predictions, the company experienced a 12% sequential demand growth. JMP analysts maintained their Market Outperform rating and $4.00 price target for Esperion, citing confidence in the company’s growth trajectory. The company also reported an expanded healthcare provider base and increased payer access, indicating a favorable position within the cardiovascular prevention market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.